However, several studies showing the relatively high efficiency of CD133+ cell-based therapies for cardiovascular disease, limb ischemia, stroke, diabetic wounds and acute lung injury11–15 suggest the possibility of using CD133+ cells to treat IAKI since all of the above-mentioned diseases share similar causes with IAKI- ischemia. This evidence concerns the gene PROM1 and cardiovascular disorder.